LCD Reference Article Response To Comments Article

Response to Comments: MolDX: Molecular Diagnostic Tests (MDT)

A54552

Expand All | Collapse All

Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	States
Noridian Healthcare Solutions, LLC	A and B MAC	01112 - MAC B	J - E	California - Northern
Noridian Healthcare Solutions, LLC	A and B MAC	01182 - MAC B	J - E	California - Southern
Noridian Healthcare Solutions, LLC	A and B MAC	01212 - MAC B	J - E	American Samoa Guam Hawaii Northern Mariana Islands
Noridian Healthcare Solutions, LLC	A and B MAC	01312 - MAC B	J - E	Nevada

Article Information

General Information

Article ID
A54552

Article Title
Response to Comments: MolDX: Molecular Diagnostic Tests (MDT)

Article Type
Response to Comments

Original Effective Date
10/01/2015

Retirement Date
N/A

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Copyright © 2024, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB‐04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution, or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312‐893‐6816.

Making copies or utilizing the content of the UB‐04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB‐04 Manual and/or codes and descriptions; and/or making any commercial use of UB‐04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.

Article Guidance

Article Text
Noridian’s Response to Provider Recommendations (for comment period ending 03/30/2015):

Response To Comments

Number	Comment	Response
1	MolDX program and expansion to other MACs creates beneficiary access concerns. Commenter states that the actions taken by some Medicare contractors follow neither the letter nor the spirit of the law which requires that coverage decisions be transparent and based on medical evidence. This commenter expressed concern that Medicare assumes that tests performed primarily in pediatric populations would never have other uses in adults that would be covered by Medicare, particularly younger disabled beneficiaries. The commenter states that this adverse impact can be magnified in that Medicaid and private payers emulate Medicare coverage determinations.	Inconsistent coverage policies from one MAC to another create beneficiary access concerns. Medicare supports consistent policies for consistent access. All policies have been developed and comply with Medicare requirements. Based on similar concerns raised by this same commenter, CMS has reviewed the molecular diagnostic policies developed to date, and found all have complied completely with both the spirits and the letter of the law. The Medicare benefit applies to the aged (>65 years) and the disabled. For the unusual situations where genetic testing for genes predominately used in perinatal, pediatric or adolescent assessment is medically indicated for a disabled or aged person, the provider can appeal this decision with submission of medical records supporting the medical necessity for testing and how the results change medical management in cases that would be exceptions to the core policy. Medicaid and private payers are responsible for determining their own coverage decisions. Medicare contractors establish coverage within the reasonable and necessary criteria of the Medicare program and they do not make coverage or payment determinations for other entities.
2	MolDX circumvents LCD process and does not allow input in coverage process. The commenter states “the program lacks the transparency that the LCD process creates in determining coverage policy. The MolDX program by way of the Technical Assessment (TA) process is making local coverage determinations for each TA request and posting the decision on-line on the Program webpage. This does not follow the LCD process of presenting coverage for a medical procedure as a draft decision to the public, the medical community, and the CAC, and providing a Comment and Notice Period as required. The use of an internal technical assessment process by the MolDX program does not replace the established requirements that define the LCD and the LCD process.” The commenter goes on to state “This is in contrast to the Article format, which is associated with a LCD and provides additional educational information about the LCD and the coding guidelines. The coding guidelines could include definitions of codes, lists of items that may be billed under a particular code and minimum requirements that providers must meet in order to bill using a certain code. It could also include a product classification list that would inform providers about which specific products meet the requirements of a specific code.”	The commenter provides no specific LCDs or articles that have not complied with the LCD process. In fact, this commenter has responded to every MolDX, laboratory and pathology LCD put forth by the CMS MolDX Contractor and/or Noridian. The current policy does not address “reasonable and necessary” criteria for a specific test. This policy defines the process by which this contractor (Noridian, and previously the CMS MolDX Contractor ) makes a coverage determination. Specifically, it requires that 1) all molecular testing within the contractor’s jurisdiction will require a unique identifier to uniquely identify every molecular tests, and 2) that all new tests coming to market must submit documents for a technical assessment (TA). The commenter indicates that the policy refers to the website for specific coding and billing information which is correct and expressly forbidden from being in the text of the policy.
3	The action proposed in this policy represents a withdrawal of coverage for Molecular Pathology Testing. The commenter wants molecular testing to be covered unless there is evidence the testing is NOT safe and effective. The commenter also wants Noridian to retract its position that all molecular testing will not be covered, or cover on a case-by-case basis until the TA is completed.	Historically, when a lab developed an assay, it marketed to providers who ordered the test and the labs submitted a claim. The MDT policy is a restatement that tests must meet “reasonable and necessary” criteria for coverage. This is not new information to providers but what is new is that the enforcement (submission of data to support reasonable and necessary) is being applied. There is no coverage of new tests until a TA is submitted and reviewed. Testing that is “safe and effective” can be likened to an assay having analytical and clinical validity. CMS requires that a test must be “reasonable and necessary” as demonstrated by the test’s clinical utility in that it improves patient outcomes or changes physician management decisions that improve patient outcomes. Noridian will not retract its position, nor cover new tests on a cases-by-case basis until the TA is completed. Once the TA is completed and the test approved, Noridian will, upon request, allow coverage from the effective date established by the CMS MolDX Contractor. The commenter is incorrect with their statement that the CMS MolDX Contractor covers these tests on a case-by-case basis until the TA is complete.
4	Unique Test Identifier Requirement Difficulty identifying tests performed from the claim form; the commenter believes Tier 1 codes are sufficient. Commenters expressed concern regarding the need for the unique identifier.	Tier 1 codes add a level of specificity, but not enough to discern and apply coverage. Unique identifiers allow the necessary specificity to establish edits to provide the differential reimbursement.
5	Unique Test Identifier Requirement Need to verify AV/CV of test performed; the commenter states that “CLIA established quality standards for laboratories to ensure the accuracy, reliability and timeliness of patient test results regardless of where the test is performed. Analytical validity is already addressed by CLIA regulations, which require laboratories to demonstrate analytical validity and regular proficiency testing.”	CLIA does not require AV or CV review of each new test introduced into a lab’s test menu. A CLIA inspection is a general overview of the lab – not the individual characteristics of a given test. CLIA looks at QC, proficiency testing, SOPs, educational qualifications of employees, criteria of the lab director, space, expired reagents, etc. Furthermore, CLIA allows a lab to perform testing for upwards of 2 years prior to a lab inspection. Nothing within a CLIA certification would provide evidence of clinical utility that establishes the ‘reasonable and necessary’ expectation of any specific test performed by that lab.
6	Unique Test Identifier Requirement Ensure claims are not being paid on asymptomatic persons – commenter agrees that this is an importance issue but disagrees that a unique identifier helps address the problem.	A unique identifier does help address the problem by providing additional information that can be applied via claim system editing rules.
7	Need to address Clinical Utility of a test; this should not be done by an outside organization; CU should go through the LCD process; accused the CMS MolDX Contractor of not adhering to the process.	The LCD process is being used as prescribed and specifically it is used to summarize the review of all evidence that was conducted in formulating the policy as it pertains to the reasonable and necessary standard of which part of that is the test’s ‘clinical utility’ as presented by the developer lab. This review is posted for public and specific CAC membership comment as required. As we are doing here, any comments are addressed as part of that process. If the commenter(s) provides significant and actionable additional information that should have been considered in the formation of the policy, a policy revision would be noted.
8	Performing 3 or more test creates “new test” to be reviewed for medical necessity.	There is no language in the MDT draft LCD policy that 3 tests performed in a series (reflex testing – next test depends on the result of the previous test) is considered a new test that requires AV/CV/CU.
9	Will the test results provide the clinician with information that will improve patient outcomes and/ or change physician care and treatment of the patient?” and “Will risk assessment change management of the patient?” It is unclear in the draft policy whether a test must meet all or only some of the listed bullet points to qualify for coverage or whether these are simply listed considerations in arriving at coverage decisions. Regardless, we have significant concerns about the proposed coverage of some of these tests. We are not aware that the following tests listed have met the above stated standards in prospectively randomized appropriate clinical trials published in peer reviewed medical journals which would allow physicians to reasonably answer affirmatively the above two questions. We suggest therefore that for the listed tests below, they prima facie do not meet the statutory requirement for coverage as “reasonable and necessary”. If these tests have indeed in your judgement met this standard, we would ask for the publication references justifying such appropriate clinical use of the following listed tests which are proposed to be covered: a) Afirma b) Allomap c) Avise PG d) ConfirmMdx Epigenetic e) Progensa PCA3 f) Tissue of Origin g) Vectra DA h) Vysis.	These tests may in fact have been covered, either by policy or lack thereof, prior to the development of the MolDX program. Contractors routinely review claims and other data (i.e. technology changes, clinical publications, professional association guideline updates) to determine impacts to existing policies and coverage. They can and will review the existing coverage criteria to determine if changes to that coverage are needed based on new evidence. This can include new or revised LCD development that would follow the LCD process should the change result in a limitation/restriction of any existing coverage. Commenters wishing to address the coverage of these tests can do so by following the LCD reconsideration process, available on all Medicare contractor websites.

Coding Information

Bill Type Codes

Code	Description
Please accept the License to see the codes.

Revenue Codes

Code	Description
Please accept the License to see the codes.

CPT/HCPCS Codes

Expand All | Collapse All

Please accept the License to see the codes.

ICD-10-CM Codes that Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-CM Codes that DO NOT Support Medical Necessity

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

ICD-10-PCS Codes

Expand All | Collapse All

Group 1

Group 1 Paragraph

N/A

Group 1 Codes

N/A

Additional ICD-10 Information

Bill Type Codes

Code	Description
Please accept the License to see the codes.

Revenue Codes

Code	Description
Please accept the License to see the codes.

Coding Table Information

Excluded CPT/HCPCS Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion
			N/A	N/A

Non-Excluded CPT/HCPCS Ended Codes - Table Format

Code	Descriptor Generic Name	Descriptor Brand Name	Exclusion Effective Date	Exclusion End Date	Reason for Exclusion

Revision History Information

N/A

Associated Documents

Related Local Coverage Documents
LCDs
L35160 - MolDX: Molecular Diagnostic Tests (MDT)

Updated On	Effective Dates	Status
07/21/2015	10/01/2015 - N/A	Currently in Effect	You are here

Keywords

Molecular
Diagnostic
MDT
MolDx

Read the Article Disclaimer

License Agreements
American Medical Association Current Procedural Terminology
American Dental Association Current Dental Terminology
American Hospital Association NUBC UB-04

Please review the licensing information below and indicate your agreement and acceptance.

License for Use of Current Procedural Terminology (CPT)

End User Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2023 American Medical Association. All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the American Medical Association (AMA).

You, your employees, and agents are authorized to use CPT only as agreed upon with the AMA internally within your organization within the United States for the sole use by yourself, employees, and agents. Use is limited to use in Medicare, Medicaid or other programs administered by the Centers for Medicare and Medicaid Services (CMS). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized herein must be obtained through the AMA, CPT Intellectual Property Services, AMA Plaza, 330 Wabash Ave., Suite 39300, Chicago, IL 60611-5885. Applications are available at the AMA Web site, http://www.ama-assn.org/go/cpt http://www.ama-assn.org/go/cpt.

Applicable FARS\DFARS Restrictions Apply to Government Use.

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, AMA Plaza, 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of FAR 52.227-14 (December 2007) and/or subject to the restricted rights provisions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.

The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT should be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CPT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material contained on this page. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

License For Use of Current Dental Terminology (CDT^TM)

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. By clicking below on the button labeled "I accept", you hereby acknowledge that you have read, understood, and agreed to all terms and conditions set forth in this agreement.

If you do not agree with all terms and conditions set forth herein, click below on the button labeled "I do not accept" and exit from this computer screen.

If you are acting on behalf of an organization, you represent that you are authorized to act on behalf of such organization and that your acceptance of the terms of this agreement creates a legally enforceable obligation of the organization. As used herein, "you" and "your" refer to you and any organization on behalf of which you are acting.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the American Dental Association web site, http://www.ADA.org/ http://www.ADA.org/.

Applicable Federal Acquisition Regulation Clauses (FARS)/Department of Defense Federal Acquisition Regulation supplement (DFARS) Restrictions Apply to Government Use.

Organizations who contract with CMS acknowledge that they may have a commercial CDT license with the ADA, and that use of CDT codes as permitted herein for the administration of CMS programs does not extend to any other programs or services the organization may administer and royalties dues for the use of the CDT codes are governed by their commercial license.

ADA DISCLAIMER OF WARRANTIES AND LIABILITIES

CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values, or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for software, including any CDT and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third-party beneficiary to this Agreement.

CMS DISCLAIMER

The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS disclaims responsibility for any liability attributable to end user use of the CDT. CMS will not be liable for any claims attributable to any errors, omissions, or other inaccuracies in the information or material covered by this license. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

The license granted herein is expressly conditioned upon your acceptance of all terms and conditions contained in this agreement. If the foregoing terms and conditions are acceptable to you, please indicate your agreement by clicking below on the button labeled "I Accept". If you do not agree to the terms and conditions, you may not access or use software. Instead, you must click below on the button labeled "I Do Not Accept" and exit from this computer screen.

License For Use of National Uniform Billing Committee (NUBC) UB-04

These materials contain NUBC Official UB-04 Specifications (UB-04 Data), which is copyrighted by the American Hospital Association (AHA).

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING BELOW ON THE BUTTON LABELED "I ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK BELOW ON THE BUTTON LABELED "I DO NOT ACCEPT" AND EXIT FROM THIS COMPUTER SCREEN. IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees, and agents are authorized to use UB-04 Data only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of UB-04 Data is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this Agreement. You acknowledge that the AHA holds all copyright, trademark, and other rights in UB-04 Data. You shall not remove, alter, or obscure any AHA copyright notices or other proprietary rights notices included in the materials.
Any use not authorized herein is prohibited, including, by way of illustration and not by way of limitation, making copies of UB-04 Data for resale and/or license, transferring copies of UB-04 Data to any party not bound by this agreement, creating any modified or derivative work of UB-04 Data, or making any commercial use of UB-04 Data. License to use UB-04 Data for any use not authorized herein must be obtained through the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois, 60606. Applications are available at the NUBC website, http://www.nubc.org/ http://www.nubc.org/.
The UB-04 Data included in this product is commercial technical data and/or computer databases and/or commercial computer software and/or commercial computer software documentation, as applicable, which was developed exclusively at private expense by the American Hospital Association, 155 N. Wacker Drive, Suite 400, Chicago, Illinois 60606. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2) (November 1995) and/or subject to the restrictions of DFARS 227.7202-1(a) (June 1995) and DFARS 227.7202-3(a) (June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (December 2007) and FAR 52.227-19 (December 2007), as applicable, and any applicable agency FAR Supplements, for non-Department of Defense Federal procurements.
AHA DISCLAIMER OF WARRANTIES AND LIABILITIES. UB-04 Data is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. The sole responsibility for the software, including any UB-04 Data and other content contained therein, is with the Medicare/Medicaid Contractor or the CMS; and no endorsement by the AHA is intended or implied. The AHA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The AHA is a third-party beneficiary to this Agreement.
CMS DISCLAIMER. The scope of this license is determined by the AHA, the copyright holder. Any questions pertaining to the license or use of the UB-04 Data should be addressed to the AHA. End users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE UB-04 DATA. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

Submit Feedback/Ask a Question

Response to Comments: MolDX: Molecular Diagnostic Tests (MDT)

Document Note

Note History

Contractor Information

Article Information

General Information

CMS National Coverage Policy

Article Guidance

Response To Comments

Coding Information

Bill Type Codes

Please accept the License to see the codes.

Revenue Codes

Please accept the License to see the codes.

CPT/HCPCS Codes

Please accept the License to see the codes.

CPT/HCPCS Modifiers

Group 1

ICD-10-CM Codes that Support Medical Necessity

Group 1

ICD-10-CM Codes that DO NOT Support Medical Necessity

Group 1

ICD-10-PCS Codes

Group 1

Additional ICD-10 Information

Bill Type Codes

Please accept the License to see the codes.

Revenue Codes

Please accept the License to see the codes.

Other Coding Information

Group 1

Coding Table Information

Revision History Information

Associated Documents

Keywords

Page Help for Article - Response to Comments: MolDX: Molecular Diagnostic Tests (MDT) (A54552)

Introduction

Finding a specific code

More information

Printing a Document to PDF

Get email updates

CMS & HHS WEBSITES

HELPFUL LINKS

RSS FEEDS